Approval · Notice of Compliance 16335 · 2014
AMLODIPINE: Notice of Compliance 16335
Issued November 24, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16335
- Date
- November 24, 2014
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Additional product name
- Therapeutic class
- Antihypertensive, antianginal agent
- Canadian reference product
- NORVASC (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AMLODIPINE | 02433176 | Cancelled Pre Market |
| AMLODIPINE | 02433184 | Cancelled Pre Market |
| AMLODIPINE | 02433192 | Cancelled Pre Market |
Medicinal ingredients
- AMLODIPINE BESYLATE 2.5 MG per TAB
- AMLODIPINE BESYLATE 5 MG per TAB
- AMLODIPINE BESYLATE 10 MG per TAB